Pyxis Oncology, Inc. Share Price
NASDAQ: PYXS | Micro CapPyxis Oncology, Inc. Stock Performance
Pyxis Oncology, Inc. Share Price Today
As of 19 September 2026, Pyxis Oncology, Inc.'s share price is $3.35. The stock opened at $3.42, compared to its previous close of $3.40. During today's trading session, Pyxis Oncology, Inc.'s share price traded between $3.35 and $3.42, with an average price of $3.38. Over the past 52 weeks, the stock has recorded a high of $5.55 and a low of $1.03. In terms of performance, Pyxis Oncology, Inc.'s share price has risen by 129.45% over the last six months and is up 51.24% on a year-on-year basis.
Pyxis Oncology, Inc. Share Price Chart
Pyxis Oncology, Inc. Quarterly Profit & Loss
All figures in USD
Pyxis Oncology, Inc. Annual Profit & Loss
All figures in USD
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Pyxis Oncology, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Sep 2026 | $3.27 | $3.36 | +0.60% |
Aug 2026 | $2.79 | $3.34 | +26.52% |
Jul 2026 | $3.06 | $2.64 | -12.00% |
Jun 2026 | $1.81 | $3.00 | +66.20% |
May 2026 | $1.69 | $1.80 | +5.87% |
Apr 2026 | $1.52 | $1.71 | +16.78% |
Mar 2026 | $1.40 | $1.46 | -1.02% |
Feb 2026 | $1.49 | $1.48 | +1.03% |
Jan 2026 | $1.14 | $1.46 | +26.41% |
Dec 2025 | $5.10 | $1.16 | -77.66% |
Nov 2025 | $3.65 | $5.17 | +44.62% |
Oct 2025 | $2.26 | $3.58 | +61.40% |